Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone

Nakata,Eiji; Kunisada,Toshiyuki; Fujiwara,Tomohiro; Katayama,Haruyoshi; Itano,Takuto; Ozaki,Toshifumi

doi:10.3892/ol.2024.14520

Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone

Authors:
- Eiji Nakata
- Toshiyuki Kunisada
- Tomohiro Fujiwara
- Haruyoshi Katayama
- Takuto Itano
- Toshifumi Ozaki
View Affiliations

Affiliations: Department of Orthopedic Surgery, Okayama University Hospital, Okayama 700‑8558, Japan
Published online on: June 21, 2024 https://doi.org/10.3892/ol.2024.14520
Article Number: 387

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor of bone (GCTB) is a locally aggressive intermediate bone tumor. Denosumab has shown effectiveness in GCTB treatment; however, the benefits of denosumab de‑escalation for unresectable GCTB have not been well discussed. The present study investigated the efficacy and safety of denosumab de‑escalation for GCTB. The medical records of 9 patients with unresectable GCTB or resectable GCTB not eligible for resection, who received de‑escalated denosumab treatment at Okayama University Hospital (Okayama, Japan) between April 2014 and December 2021, were retrospectively reviewed. The denosumab treatment interval was gradually extended to every 8, 12 and 24 weeks. The radiographic changes and clinical symptoms during standard and de‑escalated denosumab therapy were assessed. The denosumab interval was de‑escalated after a median of 12 months of a standard 4‑weekly treatment. Imaging showed that the re‑ossification of osteolytic lesions obtained with the 4‑weekly treatment were sustained with 8‑ and 12‑weekly treatments. The extraskeletal masses reduced significantly with standard treatment, while tumor reduction was sustained during de‑escalated treatment. During the 24‑weekly treatment, 2 patients remained stable, while 2 patients developed local recurrence. The clinical symptoms improved significantly with standard treatment and remained improved during de‑escalated treatment. There were severe adverse events including osteonecrosis of the jaw (2 patients), atypical femoral fracture (1 patient) and malignant transformation of GCTB (1 patient). In conclusion, 12‑weekly de‑escalated denosumab treatment showed clinical benefits as a maintenance treatment in patients with unresectable GCTB, in addition to sustained stable tumor control and improved clinical symptoms with standard treatment. A 24‑weekly treatment can also be administered, with careful attention paid to detecting local recurrence.

View Figures

View References

1	van der Heijden L, Dijkstra S, van de Sande M and Gelderblom H: Current concepts in the treatment of giant cell tumour of bone. Curr Opin Oncol. 32:332–338. 2020. View Article : Google Scholar : PubMed/NCBI
2	Basu Mallick A and Chawla SP: Giant cell tumor of bone: An update. Curr Oncol Rep. 22:512021. View Article : Google Scholar : PubMed/NCBI
3	Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, Pignotti E, Biagini R and Schwab JH: Giant cell tumor of the mobile spine: A review of 49 cases. Spine (Phila Pa 1976). 37:E37–E45. 2012. View Article : Google Scholar : PubMed/NCBI
4	Jamshidi K, Bagherifard A, Mirzaei A and Bahrabadi M: giant cell tumor of the sacrum: series of 19 patients and review of the literature. Arch Bone Jt Surg. 5:443–450. 2017.PubMed/NCBI
5	Tsukamoto S, Mavrogenis AF, Kido A and Errani C: Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel). 13:36472021. View Article : Google Scholar : PubMed/NCBI
6	Palmerini E, Picci P, Reichardt P and Downey G: Malignancy in giant cell tumor of bone: A review of the literature. Technol Cancer Res Treat. 1:15330338198400002019.PubMed/NCBI
7	Hosalkar HS, Jones KJ, King JJ and Lackman RD: Serial arterial embolization for large sacral giant-cell tumors: Mid- to long-term results. Spine (Phila Pa 1976). 32:1107–1115. 2007. View Article : Google Scholar : PubMed/NCBI
8	He SH, Xu W, Sun ZW, Liu WB, Liu YJ, Wei HF and Xiao JR: Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: A systematic review. Orthop Surg. 9:139–144. 2017. View Article : Google Scholar : PubMed/NCBI
9	Li H, Gao J, Gao Y, Lin N, Zheng M and Ye Z: Denosumab in giant cell tumor of bone: Current status and pitfalls. Front Oncol. 10:5806052020. View Article : Google Scholar : PubMed/NCBI
10	Palmerini E, Staals EL, Jones LB, Donati DM, Longhi A and Randall RL: Role of (Neo) adjuvant denosumab for giant cell tumor of bone. Curr Treat Options Oncol. 21:682020. View Article : Google Scholar : PubMed/NCBI
11	Gupta A, Durocher-Allen L, Popovic S, Tozer R, Yao X and Ghert M: The role of denosumab for surgical outcomes in patients with giant cell tumour of bone: A systematic review. Curr Oncol. 22:1302–1313. 2021. View Article : Google Scholar
12	van Langevelde K and McCarthy CL: Radiological findings of denosumab treatment for giant cell tumours of bone. Skeletal Radiol. 49:1345–1358. 2020. View Article : Google Scholar : PubMed/NCBI
13	Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, et al: Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
14	Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, et al: Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 14:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, et al: Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study. Lancet Oncol. 20:1719–1729. 2019. View Article : Google Scholar : PubMed/NCBI
16	Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, et al: Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 22:2860–2868. 2015. View Article : Google Scholar : PubMed/NCBI
17	Alaqaili SI, Abduljabbar AM, Altaho AJ, Khan AA and Alherabi J: A: Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: A literature review of reported cases. Cureus. 28:e37922018.PubMed/NCBI
18	Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, et al: Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur J Cancer. 76:118–124. 2017. View Article : Google Scholar : PubMed/NCBI
19	Matcuk GR Jr, Patel DB, Schein AJ, White EA and Menendez LR: Giant cell tumor: Rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol. 44:1027–1031. 2015. View Article : Google Scholar : PubMed/NCBI
20	Clemons M, Liu M, Stober C, Pond G, Jemaan Alzahrani M, Ong M, Ernst S, Booth C, Mates M, Abraham Joy A, et al: Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. J Bone Oncol. 30:1003882021. View Article : Google Scholar : PubMed/NCBI
21	Liu C, Wang L, Liu L, Zhuang J, Tang S, Zhang T, Zhou C, Feng F, Liu R, Zhang J, et al: Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: A systematic review and meta-analysis. Cancer Manag. Res. 10:3809–3823. 2018.
22	Tanikawa M, Yamada H, Sakata T and Mase M: Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report. Surg Neurol Int. 11:3702020. View Article : Google Scholar : PubMed/NCBI
23	Park A, Cipriano CA, Hill K, Kyriakos M and McDonald DJ: Malignant transformation of a giant cell tumor of bone treated with denosumab: A case report. JBJS Case Connect. 6:e782016. View Article : Google Scholar : PubMed/NCBI
24	Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN and Ueno NT: Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 102:651–657. 2010. View Article : Google Scholar : PubMed/NCBI
25	Costelloe CM, Chuang HH, Madewell JE and Ueno NT: cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 1:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE and Ueno NT: A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer. 13:24–30. 2013. View Article : Google Scholar : PubMed/NCBI
27	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987. View Article : Google Scholar : PubMed/NCBI
28	Priebe MM and Waring WP: The interobserver reliability of the revised American Spinal Injury Association standards for neurological classification of spinal injury patients. Am J Phys Med Rehabil. 70:268–270. 1991. View Article : Google Scholar : PubMed/NCBI
29	European Organisation for Research and Treatment of Cancer, . Reduced Dose-density of Denosumab for Unresectable GCTB (REDUCE). ClinicalTrials.gov Identifier: NCT03620149. National Library of Medicine; Bethesda, MD: 2021, https://www.clinicaltrials.gov/ct2/show/NCT03620149January 6–2021
30	Nakazawa T, Inoue G, Imura T, Miyagi M, Saito W, Namba T, Shirasawa E, Uchida K, Takahira N and Takaso M: Remarkable regression of a giant cell tumor of the cervical spine treated conservatively with denosumab: A case report. Int J Surg Case Rep. 24:22–25. 2016. View Article : Google Scholar : PubMed/NCBI
31	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
32	Sambri A, Medellin MR, Errani C, Campanacci L, Fujiwara T, Donati D, Parry M and Grimer R: Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection? J Orthop Sci. 25:513–519. 2020. View Article : Google Scholar : PubMed/NCBI
33	Bukata SV, Blay JY, Rutkowski P, Skubitz K, Henshaw R, Seeger L, Dai T, Jandial D and Chawla S: Denosumab treatment for giant cell tumor of the spine including the sacrum. Spine(Phila Pa 1976). 46:277–284. 2021. View Article : Google Scholar : PubMed/NCBI
34	Broehm CJ, Garbrecht EL, Wood J and Bocklage T: Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep. Med. 2015:7671982015.PubMed/NCBI
35	Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, Greco FG, Frezza AM, Casali PG and Stacchiotti S: Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review. ESMO Open. 5:e0006632020. View Article : Google Scholar : PubMed/NCBI